ArticlePancreas2025
Significance of Pancreatic Steatosis as a Predictor of New-Onset Diabetes Mellitus Following Pancreatectomy.
Article in Pancreas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pancreatic Steatosis and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Systematic Review of the Current Evidence.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advancements in pancreatic surgery, new-onset diabetes mellitus following pancreatectomy (NODMP), persists, affecting patients' quality of life. Predicting NODMP before surgery could significantly enhance postoperative care.
methodsThis study included 220 patients who underwent pancreatoduodenectomy or distal pancreatectomy at Hirosaki University Hospital between January 2008 and December 2020. Patients with preoperative diabetes or <6 months' follow-up were excluded. The anticipated remnant pancreatic-to-splenic parenchyma computed tomography value ratio (remP/S ratio) was used to assess pancreatic fat content, with its cutoff determined using the receiving operator characteristic curve. Time to diabetes onset was analyzed using the Kaplan-Meier method. The risk factors for NODMP were identified using the Cox proportional hazards model.
resultsThe mean diabetes-free period was 89.2 months over a median follow-up of 25.1 months. The incidence rates of NODMP at 1, 3, and 5 years after resection were 7.21%, 21.3%, and 28.0%, respectively. The significant risk factors for NODMP identified by univariate analysis were pancreatic cancer, preoperative HbA1c >5.7%, remP/S ratio <0.66, and remnant pancreatic volume <32.7 cm3. Multivariate analysis confirmed that a remP/S ratio <0.66 and preoperative HbA1c >5.7% were independent predictors of NODMP. The risk scoring system indicated that patients with both risk factors have a fivefold higher risk of developing NODMP within 2 years compared with those without either risk factor.
conclusionsPreoperative remP/S ratio and HbA1c were significant predictors of NODMP, enabling the effective stratification of NODMP risk and facilitating the early treatment of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.